Oxandrolone for the treatment of bone marrow failure in Fanconi anemia

Pediatric Blood and Cancer

Volumn 61, Issue 1, 2014, Pages 11-19

  Rose, Susan R ^a,b   Kim, Mi Ok ^a,b   Korbee, Leslie ^a,b   Wilson, Kimberly A ^a,b,d   Ris, M Douglas ^a,b,c   Eyal, Ori ^a,b,e   Sherafat Kazemzadeh, Rosa ^a,b,f   Bollepalli, Sureka ^a,b,g   Harris, Richard ^a,b   Jeng, Michael R ^b   Williams, David A ^a,b,h   Smith, Franklin O ^a,i  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^f GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^g UNIVERSITY OF SOUTH FLORIDA   (United States)

^h BOSTON CHILDREN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Androgen; Bone marrow failure; Fanconi anemia; Virilization

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANABOLIC AGENT; HEMOGLOBIN; LEVOTHYROXINE; METFORMIN; OXANDROLONE; OXYMETHOLONE; BILIRUBIN; CREATININE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BEHAVIOR CHANGE; BONE MARROW DEPRESSION; CHILD; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG RESPONSE; EVENING DOSAGE; FANCONI ANEMIA; FEMALE; FOLLOW UP; GROWTH RATE; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; MALE; MORNING DOSAGE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTE COUNT; VIRILIZATION; WEIGHT GAIN; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG SAFETY; HEMOGLOBIN BLOOD LEVEL; TOXICITY TESTING; TREATMENT OUTCOME; TREATMENT RESPONSE; CLINICAL TRIAL; COMPLICATION; HEMOGLOBINURIA, PAROXYSMAL;

ANABOLIC AGENTS; CHILD; FANCONI ANEMIA; FEMALE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MALE; OXANDROLONE;

EID: 84891814561     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24617     Document Type: Article

References (36)

1. Rosenberg PS, Zeidler C, Bolyard AA, et al. Stable long-term risk of leukemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol 2010;150:196-199.
2. Pagano G, Youssoufian H. Fanconi anemia proteins: Major roles in cell protection against oxidative damage. Bioessays 2003;25:589-595.
3. Alter BP, Giri N, Savage SA, et al. Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol 2010;150:179-188.
4. Eiler ME, Frohnmayer D, Frohnmayer L, et al. editors. Fanconi anemia: Guidelines for diagnosis and management, 3rd edition. Eugene, OR: Fanconi Anemia Research Fund, Inc.; 2008. 391 p.
5. Rose SR, Myers KC, Rutter MM, et al. Endocrine phenotype of children and adults with Fanconi anemia. Pediatr Blood Cancer 2012;59:690-696.
6. Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003;101:1249-1256.
7. Farzin A, Davies SM, Smith FO, et al. Matched sibling donor hematopoietic stem cell transplantation in Fanconi anemia: An update of the Cincinnati Children's experience. Br J Haematol 2007;136:633-640.
8. Macmillan ML, Wagner JE. Haematopoeitic cell transplantation for Fanconi anemia-When and how? Br J Haematol 2010;149:14-21.
9. Shimada A, Takahashi Y, Muramatsu H, et al. Excellent outcome of allogeneic bone marrow transplantation for Fanconi anemia using fludarabine-based reduced-intensity conditioning regimen. Int J Haematol 2012;95:675-679.
10. Stepensky P, Shapira MY, Balashov D, et al. Bone marrow transplantation for Fanconi anemia using fludarabine-based conditioning. Biol Blood Marrow Transplant 2011;17:1282-1288.
11. Thakar MS, Kurre P, Storb R, et al. Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant 2011;46:539-544.
12. Donahue RE, Tuschong L. Bauer TR, Jr., et al. Leukocyte integrin activation mediates transient neutropenia after G-CSF administration. Blood 2011;118:4209-4214.
13. Alter BP, Young NS. The bone marrow failure syndromes. In: Nathan DG, Oski FA, editors. Hematology of infancy and childhood. Philadelphia, PA: WB Saunders; 1997. pp. 227-335.
14. Medeiros C, Zanis-Neto J, Pasquini R. Bone marrow transplantation for patients with Fanconi anemia: Reduced doses of cyclophosphamide without irradiation as conditioning. Bone Marrow Transplant 1999;24:849-852.
15. Sablosky L, Sablosky R. An alternative to oxymetholone: One family's experience. Fanconi Anemia Research Fund Family Newsletter; 2000. 9.
16. Scheckenbach K, Morgan M, Filger-Brillinger J, et al. Treatment of the bone marrow failure in Fanconi anemia patients with danazol. Blood Cells Mol Dis 2012;48:128-131.
17. Menke LA, Sas TC, de Muinck Keizer-Schrama SM, et al. Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome. J Clin Endocrinol Metab 2010;95:1151-1160.
18. Gault EJ, Perry RJ, Cole TJ, et al. Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: Randomized, double blind, placebo controlled trial. Br J Haematol 2011;342:d1980.
19. Zeger MP, Shah K, Kowal K, et al. Prospective study confirms oxandrolone-associated improvement in height in growth hormone-treated adolescent girls with Turner syndrome. Horm Res Paediatr 2011; 75:38-46.
20. Wajnrajch MP, Gertner JM, Huma Z, et al. Evaluation of growth and hormonal status in patients referred to the International Fanconi Anemia Registry. Pediatrics 2001;107:744-754.
21. Giri N, Batista DL, Alter BP, Stratakis CA, Endocrine abnormalities in patients with Fanconi anemia. J Clin Endocrinol Metab 2007;92:2624-2631.
22. Ferriman D, Gallwey JD, Clinical assessment of body hair growth in women. Endocrinol Metab 1986;21:1440-1447.
23. Tagatz GE, Kopher RA, Nagel TC, et al. The clitoral index: A bioassay of androgenic stimulation. Obstet Gynecol 1979;54:562-564.
24. Reynolds CR, Kamphaus RW. Behavioral assessment system for children manual. Circle Pines, MN: American Guidance Service, Inc.; 1992.
25. Allen DM, Fine MH, Necheles TF, et al. Oxymetholone therapy in aplastic anemia. Blood 1968;32: 83-89.
26. The Cooperative Group for the Study of Aplastic Anemias. Androgen therapy of aplastic anemia-A prospective study of 352 cases. Scand J Haematol 1979;22:343-356.
27. Fox-Wheeler S, Heller L, Salata CM, et al. Evaluation of the effects of oxandrolone on malnourished HIV-positive pediatric patients. Pediatrics 1999;104:e73. DOI: 10.1542/peds.104.6.e73
28. Przkora R, Jeschke MG, Barrow RE, et al. Metabolic and hormonal changes of severely burned children receiving long-term oxandrolone treatment. Ann Surg 2005;242:384-391.
29. Sanchez-Medal L. The hemopoietic action of androstanes. Prog Hematol 1971;7:111-136.
30. Gorshein D, Murphy S, Gardner FH, Studies on the erythropoietic activity of steroid metabolites. Exp Hematol 1973;1:123-126.
31. Gorshein D, Murphy S, Gardner FH. Comparative study on the erythropoietic effects of androgens and their mode of action. J Appl Physiol 1973;35:276-278.
32. Kamamoto T, Ohkubo T, Yamagishi M, et al. Correlation between in vitro and in vivo response to androgens in patients with aplastic anemia. Int J Cell Cloning 1984;2:173-184.
33. Kim SW, Hwang JH, Cheon JM, et al. Direct and indirect effects of androgens on survival of hematopoietic progenitor cells in vitro. J Korean Med Sci 2005;20:409-416.
34. Calado RT, Yewdell WT, Wilkerson KL, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood. 2009;114:2236-2243.
35. Guo C, Armbruster BN, Price DT, Counter CM, In vivo regulation of hTERT expression and telomerase activity by androgen. J Urol 2003;170:615-618.
36. Ziegler P, Schrezenmeier H, Akkad J, et al. Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation. Ann Hematol 2012;91:1115-1120.